Last updated 2026-07-20
- Raised $120M Seed round led by Marius Nacht, Nov 2021
Total raised
$120.0M
Last: Undisclosed Round 2021-12
Stage
Seed
Founded
2021
Headcount
47
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
1E Therapeutics is an innovative pharmaceutical firm specializing in the development of RNA-targeting medications using a unique drug design platform. Their groundbreaking process has proven uniquely able to develop innovative drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders. The company is developing a new modality of RNA silencing that is independent of cellular machinery, allowing for high specificity at the single-letter level.
Funding history · 1 round · $120.0M total
2021-11
Seed
$120.0M
★ Marius Nacht
Headcount over time
From 3 (2021-06) to 48 (2025-12) · +45 (+1500%) · 33 points · source: Finder history + radar grounding
Q&A
- What is 1E Therapeutics' primary focus?
- 1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform.
- When was 1E Therapeutics founded?
- 1E Therapeutics was founded in July 2021.
- What is the total amount of funding 1E Therapeutics has raised?
- 1E Therapeutics has raised a total of $120,000,000 USD.
- Who was a lead investor in 1E Therapeutics' funding round in December 2021?
- Marius Nacht was a lead investor in 1E Therapeutics' funding round in December 2021.
- How many employees does 1E Therapeutics currently have?
- 1E Therapeutics has 11-50 employees.
- In which country is 1E Therapeutics headquartered?
- 1E Therapeutics is headquartered in Israel.
- What types of indications does 1E Therapeutics' drug development process address?
- 1E Therapeutics' process develops drugs that address chronic life-threatening indications, emerging and evolving pathogens, and has lead compounds for oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.
- What is the current product stage of 1E Therapeutics?
- 1E Therapeutics is currently in the clinical trial stage.
Team · 1
Ido Bachelet
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
genetic-disorderscancerpharmaceuticalschronic-diseaseimmunologyviral-diseasesoncologypharma-companiesdrug-developmenttherapeuticsinfectious-disease
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | 1etx.com |
|---|---|
| linkedin.com/company/72749387 |
Identifiers & details
| Legal name | 1E THERAPEUTICS LTD |
|---|---|
| Founded | 2021-7 |
| Employees (exact) | 47 |
Radar intelligence
Patents
| EPO | 7 |
|---|
Web history (Wayback)
| Domain | 1etx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516431137 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-07-11 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 3 — shares_capital (1), annual_report (1), people (1) |
| Registered address | הולצמן חיים 8 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-20 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2026-01-19 | דו~ח שנתי |
| 2025-08-10 | עדכון בעלי תפקידים |